Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Instem Enters Early Phase Clinical Market

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
Instem has acquired Logos Technologies representing its strategic move into the early phase clinical trials market.

Logos is headquartered in London with staff located both in the United Kingdom and the United States, Logos is well known for providing its customers with quality products that are developed following GCP regulatory requirements along with high caliber subject matter experts to help streamline clinical trials and reduce drug development time.

The ALPHADAS® software solution suite is a proactive eSource clinical trials system that is mobile, schedule-driven, and provides real-time bedside or station based direct data capture that virtually eliminates paper-based data. ALPHADAS delivers enhanced quality, operational efficiencies and time savings across the clinic, data management, recruitment, site administration and the laboratory.

“Instem has a fantastic reputation in the pharmaceutical industry for innovative and quality software solutions backed by outstanding customer support,” comments Giles Wilson, CEO & founder of Logos Technologies. “The majority of our new business has come from a reputation of successful delivery of market leading products and services. Instem’s proven track record in client satisfaction along with their likeminded values was a key reason to our joining forces, as it supports our overall vision of delighting each and every client. Being part of the Instem group provides us with even greater confidence and the financial backing needed to compete at a new level as we look to accelerate our leadership position in the clinical space while being part of the larger mission to deliver data-driven insights.”

As part of their mission to deliver compelling solutions for data collection, management and analysis across the R&D continuum, Instem’s entry into the early clinical market provides greater access to early phase clinical data in both healthy and patient populations, advancing Instem’s translational informatics technology strategy.

Phil Reason, President & CEO of Instem commented, “We are delighted that the talented team at Logos will be joining the Instem group and we look forward to working together to provide valuable automation tools that will enable our clients to bring new products to market quickly and cost effectively. The ALPHADAS suite is an acknowledged leader in the early phase e-source data capture industry and the integration of the business also expands our product portfolio reach and provides avenues for extending our Provantis® and Centrus™ solutions.”

Having become the standard by which organizations across four continents accelerate and streamline clinical trial operations and service, Instem is planning a series of presentations and promotional programs to further demonstrate the value of ALPHADAS as part of the larger Instem organization.

One of the value-added offerings this acquisition will bring is the introduction of a Software-as-a-Service (SaaS) version of ALPHADAS, which will be especially useful for the many small clinical units within the early phase market. Instem’s SaaS model offers simpler, more cost effective ways to provide software functionality, maintenance, and support over the Internet.

ALPHADAS is believed to have been selected for the majority of new business placed in the early phase market in the last three years, delivering both the innovation and performance required by today’s clinical R&D units. ALPHADAS was most recently chosen by SNBL for its clinical pharmacology unit in Baltimore, Maryland.

The Powerful ALPHADAS system will enhance Instem’s Study Workflow and Automation Suite that includes solutions enabling organizations of all sizes to collect, manage, review and submit study data that streamline processes, increase quality and enhance development programs.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

JOINN Laboratories China Purchases Instem’s Preclinical Software Suite
Leading Chinese CRO selects Version 9 of Provantis integrated preclinical software to automate study processes at Beijing and Suzhou sites.
Wednesday, January 30, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos